Atlas Trials

Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)

Clinical trial NCT01274559 · TERMINATED

Trial details

NCT number
NCT01274559
Sponsor
Merck Sharp & Dohme LLC
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Primary HypercholesterolemiaMixed Dyslipidemia
Start date
2011-03-01
Primary completion
2013-02-26
Enrollment
1173

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.